Elixa Medicaments Private Limited
About Elixa Medicaments Private Limited
Data last updated:
Elixa Medicaments Private Limited is a private limited company based in Kolhapur, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 October 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U33309PN2017PTC172931. Its GSTIN is 27AAECE8157D1ZM (Maharashtra).
The company has an authorised share capital of ₹45 Lakh and a paid-up capital of ₹11.73 Lakh. It is led by directors Rashmi Rajiv Deshpande and Rajiv Vijayraj Deshpande.
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at Csno814/2/1 Awingorchidhomesfl.No.104 Eward Karandemala, Kolhapur, Maharashtra, India – 416003.
As per the financials filed for FY 2022, the company reported a revenue of ₹24.53 Lakh, a decline of 47% compared to the previous year. For the same year it recorded a net loss of ₹6,050 (net margin -0.2%) and EBITDA of -₹2,860 (EBITDA margin -0.1%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Elixa Medicaments Private Limited's registered office is in Kolhapur, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered AddressCsno814/2/1 Awingorchidhomesfl.No.104 Eward Karandemala, Kolhapur, Maharashtra, India – 416003
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Elixa Medicaments Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Elixa Medicaments is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Elixa Medicaments Private Limited, buy the company report.
Financials of Elixa Medicaments Private Limited
FY 2022 filings availableElixa Medicaments Private Limited reported revenue of ₹24.53 Lakh (down 47% YoY) for FY 2022.
Compounded Annual Growth Rate (CAGR)
Revenue fell 47% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 22%. EBITDA fell 137% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2,860 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹6,050 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -0.1% | ||||
| Net Profit Margin | -0.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Elixa Medicaments Private Limited, buy the company report.
Board of directors of Elixa Medicaments Private Limited
Elixa Medicaments has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rashmi Rajiv Deshpande | Director | 10 Oct 2017 | 9 Years 0 Months | Current |
| Rajiv Vijayraj Deshpande | Director | 18 Mar 2020 | 6 Years 7 Months | Current |
Peer comparison
Elixa Medicaments Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shivalik Prismo India Private Limited | ₹24.58 Lakh (FY 2025) | -77.0% | Chandigarh, India | |||
| Shubham Organics Limited | ₹24.57 Lakh (FY 2025) | -95.0% | Delhi, India | |||
| Engrais Solutions Private Limited | ₹24.56 Lakh (FY 2025) | 280.0% | Kolkata, West Bengal, India | |||
| Global Herbals India Private Limited | ₹24.55 Lakh (FY 2016) | 391.0% | Gurgaon, Haryana, India | |||
| Yantur Manufacturing Private Limited | ₹24.53 Lakh (FY 2025) | -72.0% | Chennai, Tamil Nadu, India | |||
| Elixa Medicaments Private Limitedthis company | ₹24.53 Lakh (FY 2022) | -₹6,050 | -0.2% | -47.0% | Kolhapur, Maharashtra, India | |
| Agrivita Science Private Limited | ₹24.51 Lakh (FY 2025) | 219.0% | Ahmedabad, Gujarat, India | |||
| Sanmak Pharmaceuticals Private Limited | ₹24.48 Lakh (FY 2019) | Haridwar, Uttarakhand, India | ||||
| Rohan Pigments P Ltd | ₹24.46 Lakh (FY 2025) | -3.0% | Dombivli, Maharashtra, India | |||
| Naipunyaaayurvedics Private Limited | ₹24.46 Lakh (FY 2024) | 44.0% | Kollam, Kerala, India | |||
| Velanutrition Nutraceuticals Private Limited | ₹24.45 Lakh (FY 2025) | 5077.0% | Udhampur, Jammu and Kashmir, India |
To see the full peer comparison of Elixa Medicaments Private Limited, buy the company report.
Shareholding
The shareholding of Elixa Medicaments Private Limited is on record for FY 2019, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2019 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Elixa Medicaments Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Elixa Medicaments Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Elixa Medicaments Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Elixa Medicaments has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAECE8157D1ZM | Maharashtra | Active | 06 Nov 2017 |
To see the full GST registrations and return filing status of Elixa Medicaments Private Limited, buy the company report.
Recent activity
Elixa Medicaments Private Limited has 4 board changes on record since 2017: 3 appointments and 1 cessation. The latest: Shreya Rajiv Deshpande ceased to be Director on 30 Apr 2020.
Frequently asked questions
Elixa Medicaments is an active private limited company based in Kolhapur, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 October 2017 (9+ years old) and is registered under CIN U33309PN2017PTC172931.
Elixa Medicaments has 2 current directors:
- Rashmi Rajiv Deshpande - Director
- Rajiv Vijayraj Deshpande - Director
The latest financial statements of Elixa Medicaments on record with the MCA are for the year ended 31 March 2022. Its last annual general meeting was held on 30 September 2022. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Elixa Medicaments is 27AAECE8157D1ZM, registered in Maharashtra.
The CIN (Corporate Identification Number) of Elixa Medicaments is U33309PN2017PTC172931. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Elixa Medicaments was incorporated on 10 October 2017, making it 9+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Elixa Medicaments by revenue are Shivalik Prismo India Private Limited, Shubham Organics Limited, Engrais Solutions Private Limited, Global Herbals India Private Limited, Yantur Manufacturing Private Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Shreya Rajiv Deshpande ceased to be Director on 30 Apr 2020. Rajiv Vijayraj Deshpande was appointed as Director on 18 Mar 2020. Rashmi Rajiv Deshpande was appointed as Director on 10 Oct 2017. Elixa Medicaments has 4 board changes on record in total.
The registered office of Elixa Medicaments is at Csno81421 Awingorchidhomesfl.No.104 Eward Karandemala, Kolhapur, Maharashtra, India – 416003.
Elixa Medicaments operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Elixa Medicaments is compliant as of 08 September 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
